Takeda plans to vacate all 1,000 staff from US HQ by the year’s end
pharmafile | June 26, 2019 | News story | Manufacturing and Production, Medical Communications, Sales and Marketing | Shire, Takeda, US, pharma
Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, Illinois, by the end of the year – a hard date was given of 31 December – with the aim of selling the 777,000-square-foot campus by 31 March 2020.
This is not an insignificant task, as the site currently employs around 1,000 workers. The strategy will see some of this workforce working remotely, while some will be moved to a transitional location, according to Takeda spokesperson Julia Ellwanger. She highlighted Shire’s former offices in Bannockburn as a transitional site, but she did not confirm how many staff would be operating there or for how long.
“Integration activities with respect to certain groups that currently reside in Deerfield are ongoing, and we are encouraged by the progress we have made thus far,” Ellwanger commented. “Managers and their teams are working to consider employee needs and the needs of the business. Where possible, roles have been designated as remote or field based, while others require co-location due to the nature of the work.
“In cases where there isn’t a solution that meets the business and/or an employee’s needs, the employee will be provided with severance and transition support programmes,” she added.
Though the Japanese firm first announced its plans to sell the site back in September last year, it was not made clear how many employees would be affected. The decision ends the company’s presence in the state after 40 years, as it moves to consolidate its US operations in Massachusetts following its acquisition of Irish pharma firm Shire.
Matt Fellows
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
